Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014).
Coinfection
/ complications
Cross-Sectional Studies
Female
HIV Infections
/ complications
HIV-1
Hepatitis Antibodies
/ blood
Hepatitis C
/ complications
Hepatitis E
/ complications
Hepatitis E virus
/ immunology
Humans
Immunoglobulin G
/ blood
Male
Middle Aged
Prevalence
RNA, Viral
/ blood
Spain
/ epidemiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 02 2019
04 02 2019
Historique:
received:
05
09
2018
accepted:
27
11
2018
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
10
9
2020
Statut:
epublish
Résumé
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm
Identifiants
pubmed: 30718554
doi: 10.1038/s41598-018-37328-6
pii: 10.1038/s41598-018-37328-6
pmc: PMC6361883
doi:
Substances chimiques
Hepatitis Antibodies
0
Immunoglobulin G
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143Références
Ann Intern Med. 2003 Apr 15;138(8):620-6
pubmed: 12693883
Clin Vaccine Immunol. 2006 Dec;13(12):1328-32
pubmed: 17050741
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):179-87
pubmed: 17075385
J Infect Dis. 2008 Apr 15;197(8):1133-44
pubmed: 18476292
Lancet. 2009 Apr 18;373(9672):1352-63
pubmed: 19361855
J Clin Virol. 2009 Jul;45(3):259-61
pubmed: 19505848
AIDS. 2010 Jun 19;24(10):1493-9
pubmed: 20467291
HIV Med. 2012 Jul;13(6):379-83
pubmed: 22257075
Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):24-33
pubmed: 23026902
J Med Virol. 2014 Jan;86(1):71-4
pubmed: 24136591
Clin Microbiol Rev. 2014 Jan;27(1):116-38
pubmed: 24396139
J Med Virol. 2014 Mar;86(3):478-83
pubmed: 24402843
AIDS. 2014 Aug 24;28(13):1931-7
pubmed: 24979724
PLoS One. 2014 Jul 28;9(7):e103028
pubmed: 25068388
Transfusion. 2015 May;55(5):972-9
pubmed: 25403913
J Infect. 2015 Jun;70(6):624-30
pubmed: 25452042
Infect Dis (Lond). 2015;47(10):707-13
pubmed: 25994453
Rev Esp Quimioter. 2015 Dec;28(6):314-6
pubmed: 26621176
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
J Clin Virol. 2016 Jul;80:102-6
pubmed: 27243210
J Clin Virol. 2016 Sep;82:9-16
pubmed: 27393938
PLoS One. 2016 Jul 28;11(7):e0160082
pubmed: 27467394
Viruses. 2016 Aug 06;8(8):
pubmed: 27509518
Zoonoses Public Health. 2017 Nov;64(7):e60-e64
pubmed: 28236361
AIDS. 2018 Jun 1;32(9):1095-1105
pubmed: 29438197
J Med Virol. 2018 Jun;90(6):1121-1127
pubmed: 29457639